Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Freestyle Libre Flash Glucose Monitoring System

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03607448
Recruitment Status : Completed
First Posted : July 31, 2018
Last Update Posted : November 29, 2018
Information provided by (Responsible Party):
Abbott Diabetes Care

Brief Summary:
The purpose of this study is to characterize the Freestyle Libre Flash Glucose Monitoring System performance with respect to YSI reference venous plasma sample measurements.

Condition or disease Intervention/treatment
Diabetes Mellitus Device: Freestyle Libre Flash Glucose Monitoring System

Detailed Description:
Up to 200 subjects will be enrolled in this study at a total of 6 clinical research sites in the United States. Subjects will wear a total of two (2) sensors, one on the back of each upper arm. Each Sensor will have a paired Reader that will be given to the subject. All Readers will be masked during the study (i.e. subjects will not be able to view glucose results obtained from the Sensor on the Reader screen). Subjects will be asked to perform at least 8 capillary Blood Glucose (BG) tests per day using the primary Reader. Interstitial glucose readings from each Sensor will be obtained with the corresponding Readers immediately following each BG test. Subjects will be instructed to report any problems with the device. Subjects will make six (6) scheduled visits to the clinical study site, including the Enrollment/Screening Visit (Visit 1). Subjects will have three (3) in-clinic visits during which intravenous blood draws and YSI reference testing will occur.

Layout table for study information
Study Type : Observational
Actual Enrollment : 153 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Freestyle Libre Flash Glucose Monitoring System Accuracy Study
Actual Study Start Date : July 23, 2018
Actual Primary Completion Date : November 21, 2018
Actual Study Completion Date : November 21, 2018

Resource links provided by the National Library of Medicine

Drug Information available for: Dextrose

Group/Cohort Intervention/treatment
Diabetes Mellitus Type 1 and Type 2
Subjects will wear the Abbott Sensor Based Glucose Monitoring Systems and expected to perform at least 8 capillary BG test per day. Site Staff will determine when subject will undergo either a hypoglycemia induction or a hyperglycemia induction. Study staff will perform IV blood draw to obtain blood plasma for YSI sampling every 15 min when glucose as measured by YSI is above 70mg/dL and below 240 mg/dL.
Device: Freestyle Libre Flash Glucose Monitoring System
Subjects will wear the Abbott Sensor based FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes

Primary Outcome Measures :
  1. System Performance [ Time Frame: approximately 45 days ]
    System Performance will be characterized with respect to YSI reference venous plasma measurements

Secondary Outcome Measures :
  1. System Related Adverse Device Effects [ Time Frame: Up to 45 days ]
    System will be characterized by Adverse Device Effects and Serious Adverse Device Effects experienced by study participants

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Subjects with Type 1 or Type 2 diabetes requiring multiple daily insulin injections (MDI) or continuous subcutaneous insulin infusion (CSII).

Inclusion Criteria:

  • Subject must be at least 18 years of age.
  • Subject must have type 1 or type 2 diabetes.
  • Subject must require insulin therapy through an insulin pump and/or multiple daily insulin injections (at least 3 injections daily).
  • Willing to perform a minimum of 8 finger sticks per day while wearing the sensor in the study.
  • Subject must be able to read and understand English.
  • Willing to have their blood sugar manipulated during in-clinic sessions.
  • In the investigator's opinion, the subject must be able to follow the instructions provided to him/her by the study site and perform all study tasks as specified by the protocol.
  • At the time of enrollment, subject must be available to participate in all study visits.
  • Subject must be willing and able to provide written signed and dated informed consent.
  • Additional criteria for hypoglycemia induction.
  • Known insulin sensitivity factor.

Exclusion Criteria:

  • Subject has a history of hypoglycemia unawareness.
  • Subject has known allergy to medical grade adhesive or isopropyl alcohol used to disinfect skin.
  • Subject is pregnant, attempting to conceive or not willing and able to practice birth control during the study duration (applicable to female subjects only).
  • Subject has extensive skin changes/diseases at the proposed application sites that could interfere with device placement or the accuracy of interstitial glucose measurements. Such conditions include, but are not limited to extensive psoriasis, recent burns or severe sunburn, extensive eczema, extensive scarring, dermatitis herpetiformis, skin lesions, redness, infection or edema.
  • Subject has had an episode of severe hypoglycemia requiring intervention from a health care professional (i.e. EMT assistance, emergency room visit, or hospital admission) within the last three (3) months.
  • Subject is currently participating in another clinical trial.
  • Subject has donated blood within 112 days (3.7 months) prior to the beginning of the study activities.
  • Subject has both hemoglobin (Hb) and hematocrit levels that are 10% or more below the normal ranges (For reference low end of the normal range for Hb for males is 14 g/dL and for females is 12 g/dL; low end of the normal hematocrit is 40% for men and 36% for women).
  • Subject has concomitant medical condition which, in the opinion of the investigator, could present a risk to the safety or welfare of the subject or study staff. Such conditions include but are not limited to:
  • History of HIV, Hepatitis B or C
  • Subject has X-ray, MRI, CT or diathermy appointment scheduled during the period of study participation, and the appointment cannot be rescheduled for a time before study participation starts or after study participation ends.
  • Subject is unsuitable for participation due to any other cause as determined by the Investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03607448

Layout table for location information
United States, California
Escondido, California, United States, 92025
Sansum Diabetes Research Institute
Santa Barbara, California, United States, 93105
Diablo Clinical Research
Walnut Creek, California, United States, 94598
United States, Idaho
Rocky Mountain Diabetes and Osteoporosis Center
Idaho Falls, Idaho, United States, 94502
United States, Washington
Rainier Clinical Research Center
Renton, Washington, United States, 98057
Sponsors and Collaborators
Abbott Diabetes Care
Layout table for investigator information
Study Director: Shridhara Karinka, PhD Abbott Diabetes Care
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Abbott Diabetes Care Identifier: NCT03607448    
Other Study ID Numbers: ADC-US-VAL-18174
First Posted: July 31, 2018    Key Record Dates
Last Update Posted: November 29, 2018
Last Verified: November 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes